0000899243-23-012347.txt : 20230505 0000899243-23-012347.hdr.sgml : 20230505 20230505161011 ACCESSION NUMBER: 0000899243-23-012347 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230428 FILED AS OF DATE: 20230505 DATE AS OF CHANGE: 20230505 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Aromando Andrew CENTRAL INDEX KEY: 0001976455 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40505 FILM NUMBER: 23893902 MAIL ADDRESS: STREET 1: C/O AMBRX BIOPHARMA INC. STREET 2: 10975 NORTH TORREY PINES ROAD CITY: LA JOLLA STATE: CA ZIP: 92037 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Ambrx Biopharma Inc. CENTRAL INDEX KEY: 0001836056 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 571147346 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 10975 NORTH TORREY PINES ROAD CITY: LA JOLLA STATE: CA ZIP: 92037 BUSINESS PHONE: (858) 875-2400 MAIL ADDRESS: STREET 1: 10975 NORTH TORREY PINES ROAD CITY: LA JOLLA STATE: CA ZIP: 92037 4 1 doc4.xml FORM 4 SUBMISSION X0407 4 2023-04-28 0 0001836056 Ambrx Biopharma Inc. AMAM 0001976455 Aromando Andrew C/O AMBRX BIOPHARMA INC., 10975 TORREY PINES ROAD LA JOLLA CA 92037 0 1 0 0 Chief Operating Officer 0 Stock Option (right to buy) 1.38 2023-04-28 4 A 0 2600000 0.00 A 2033-04-28 Ordinary Shares 2600000 2600000 D The options will have an exercise price per share equal to the fair market value per ordinary share on the grant date based on the trading price of the Issuer's American Depositary Shares ("ADSs"). Grant awarded as an inducement grant in connection with the Reporting Person's appointment as Chief Operating Officer of the Issuer. Twenty-five percent of the Ordinary Shares subject to the option vested on April 28, 2024, and the remainder vests in thirty-six equal monthly installments following such date. The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents seven Ordinary Shares of the Issuer. /s/ Sonja Nelson, Attorney-in-Fact for Andrew Aromando 2023-05-05